Phase 1 Clinical trial

Title Average Ratingsort ascending
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. 90.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
Metabolic modulation of glioblastoma with dichloroacetate. 90.00%
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. 90.00%
Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia. 90.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid An 80.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. 75.00%
Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man. 70.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. 70.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli 70.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. 70.00%
Clinical studies of Ukrain in healthy volunteers (phase 1). 60.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. 60.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... 60.00%
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. 60.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ 60.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. 40.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... 30.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. 30.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. 10.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%